Digicann Ventures Past Earnings Performance
Past criteria checks 2/6
Digicann Ventures has been growing earnings at an average annual rate of 26.5%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 13.6% per year.
Key information
26.5%
Earnings growth rate
47.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 13.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Digicann Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 15 | 1 | 0 |
| 30 Sep 23 | 1 | -15 | 2 | 0 |
| 30 Jun 23 | 1 | -17 | 2 | 0 |
| 31 Mar 23 | 1 | -23 | 2 | 0 |
| 31 Dec 22 | 1 | -20 | 2 | 0 |
| 30 Sep 22 | 1 | 0 | 3 | 0 |
| 30 Jun 22 | 1 | 1 | 3 | 0 |
| 31 Mar 22 | 1 | -1 | 4 | 0 |
| 31 Dec 21 | 1 | -1 | 5 | 0 |
| 30 Sep 21 | 1 | -83 | 8 | 0 |
| 30 Jun 21 | 1 | -88 | 11 | 0 |
| 31 Mar 21 | 1 | -91 | 15 | 0 |
| 31 Dec 20 | 1 | -103 | 18 | 1 |
| 30 Sep 20 | 1 | -66 | 14 | -11 |
| 30 Jun 20 | 1 | -98 | 47 | 1 |
| 31 Mar 20 | 0 | -104 | 54 | 1 |
| 31 Dec 19 | 0 | -101 | 56 | 0 |
| 30 Sep 19 | 0 | -57 | 55 | 12 |
| 30 Jun 19 | 0 | -21 | 19 | 0 |
| 31 Mar 19 | 0 | -10 | 8 | 0 |
| 31 Dec 18 | 0 | -6 | 5 | 0 |
| 30 Sep 18 | 0 | -6 | 6 | 0 |
| 30 Jun 18 | 0 | -5 | 5 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -3 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -1 | 1 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
| 30 Jun 15 | 0 | -1 | 1 | 0 |
| 31 Mar 15 | 0 | -1 | 1 | 0 |
| 31 Dec 14 | 0 | -1 | 1 | 0 |
| 30 Sep 14 | 0 | -3 | 1 | 0 |
| 30 Jun 14 | 0 | -3 | 1 | 0 |
| 31 Mar 14 | 0 | -2 | 1 | 0 |
| 31 Dec 13 | 0 | -2 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
Quality Earnings: DCNN has a large one-off gain of CA$17.9M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: DCNN became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DCNN has become profitable over the past 5 years, growing earnings by 26.5% per year.
Accelerating Growth: DCNN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: DCNN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: DCNN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.